Wagner, Robert http://orcid.org/0000-0002-6120-0191
Eckstein, Sabine S.
Yamazaki, Hajime
Gerst, Felicia
Machann, Jürgen http://orcid.org/0000-0002-4458-5886
Jaghutriz, Benjamin Assad
Schürmann, Annette
Solimena, Michele http://orcid.org/0000-0002-3653-8107
Singer, Stephan
Königsrainer, Alfred
Birkenfeld, Andreas L. http://orcid.org/0000-0003-1407-9023
Häring, Hans-Ulrich
Fritsche, Andreas
Ullrich, Susanne
Heni, Martin http://orcid.org/0000-0002-8462-3832
Article History
Accepted: 13 September 2021
First Online: 20 October 2021
Competing interests
: Since January 2020, B.A.J. has been an employee and shareholder of Eli Lilly and Company. Outside the current work, R.W. reports lecture fees from Novo Nordisk and Sanofi, and travel grants from Eli Lilly. R.W. served on an advisory board for Akcea Therapeutics and Daiichi Sankyo. In addition to his current work, A.L.B. reports lecture fees from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. A.L.B. served on advisory boards for AstraZeneca, Boehringer Ingelheim and Novo Nordisk. Besides his current work, A.F. reports lecture fees from and advisory board membership for Sanofi, Novo Nordisk, Eli Lilly and AstraZeneca. In addition to his current work, M.H. reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tübingen) and lecture fees from Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Merck Sharp & Dohme. He also served on an advisory board for Boehringer Ingelheim. The other authors declare no competing interests.